XTL BIOPHARMACEUTICALS LTD (XTLB): Financial results for H1 2026

XTL BIOPHARMACEUTICALS LTD (XTLB) furnished an SEC Form 6-K — earnings release. RAMAT GAN, ISRAEL - (November 18, 2026) – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) (“XTL” or the “Company”) today announced financial results for the six months ended June 30, 2026. On June 30, 2026, the Company completed the acquisition of 83.4% of the share cap

Event · Earnings
Original reporting
Published Nov 18, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$XTLB
Bearish
high confidence
Mentioned
$XTLB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$XTLBBearishMed
01

Why it matters

The earnings release provides the first public details on the Psyga acquisition and recent financing, offering fresh data for valuation.

02

Market read

The filing is a primary source of new financial and transaction data for XTL, but its small size limits broader market impact.

03

What to watch

Potential future revenue from Psyga's pipeline and the strategic value of the contingent warrants are not reflected in the current loss.

Relevance 7/10Novelty 6/10Timing: today

Background

XTL Biopharmaceuticals is a NASDAQ‑listed micro‑cap focused on psychedelic‑based drug development.

Company-level read

Ticker impact

$XTLBBearishHigh confidence
Context

XTL Biopharmaceuticals filed a Form 6‑K reporting H1 2026 results, including a $3.5 M acquisition of Psyga Bio and a $1.5 M private placement.

Expected impact

likely downward pressure as investors digest the loss and dilution

Evidence & confidence

The company posted a loss, no operating revenue, and issued new shares/warrants, which typically weigh on a micro‑cap's stock.

Market effects

Highlights ongoing consolidation in the psychedelic‑biotech niche, but limited broader sector impact.

Primarily affects Israeli biotech investors; minimal effect on broader US markets.

Low global relevance due to small scale and niche focus.

Counterpoint

If the acquisition unlocks valuable mushroom‑derived therapeutics, the dilution could be justified and the stock may rebound.

Key entities

  • XTL Biopharmaceuticals Ltd.

    Issuer of the 6‑K filing.

  • Psyga Bio Ltd.

    Israeli biotech acquired by XTL.

Related articles

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.

$IPARMedAI 8/10

INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE New York, New York, November 18, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In

$WWDMedAI 8/10

Woodward falls on soft guidance despite fourth quarter beat

Woodward Inc (WWD) reported Q4 2026 adjusted EPS of $2.83, beating estimates by $0.30, and revenue of $1.2B, up 17% YoY. However, its fiscal 2027 guidance fell short of expectations, with EPS projected at $10.20-$10.70, below the $10.76 consensus. Shares dropped 1.7% in after-hours trading. The company reported full-year 2026 adjusted EPS of $9.78, up 42% YoY, and net sales of $4.4B, up 22% YoY.

$KRNTMedAI 8/10

Kornit (KRNT) Q3 2026 Earnings Call Transcript

Kornit (KRNT) reported Q3 2026 revenue of $58.3M, up 9.8% YoY. The company highlighted growth in recurring revenue, with 80% of revenue being recurring or highly recurring. Annual recurring revenue (ARR) reached $39.4M, up 83% YoY. Kornit expects Q4 revenue between $60M and $65M, with adjusted EBITDA margin between 6.5% and 9%. The company is seeing strong adoption of its all-inclusive click (AIC) model and is expanding its customer base, including traditional screen printers.

$SNEXMedAI 8/10

StoneX Group falls after fourth quarter earnings miss

StoneX Group Inc. (SNEX) reported Q4 earnings of $0.66 per share, missing estimates of $0.81. Revenue rose 12% YoY to $655.2M, but net income fell 2% to $84.2M. Full-year 2026 results showed record net income of $525.4M, up 72% YoY, and revenue of $2.9B, up 43% YoY. The stock dropped 6.2% in after-hours trading.

$AUNAMed

Auna (AUNA) Q3 2026 Earnings Call Transcript

Auna (AUNA) reported Q3 2026 earnings, highlighting 10% top-line growth on an FX-neutral basis. Mexico saw accelerated growth and profitability, while Colombia faced medical cost pressures. Peru's revenue grew, but profitability declined due to penalties. The company maintained strong cash generation, reducing leverage to 3.5x. Auna remains confident in its long-term growth potential.